NewAmsterdam Pharma Company N.V. (NAMS)
- Previous Close
19.27 - Open
19.29 - Bid 18.01 x 600
- Ask 19.01 x 600
- Day's Range
18.26 - 19.83 - 52 Week Range
14.06 - 27.29 - Volume
964,566 - Avg. Volume
1,018,065 - Market Cap (intraday)
2.062B - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-2.56 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.57
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
www.newamsterdampharma.comRecent News: NAMS
View More
Performance Overview: NAMS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAMS
View MoreValuation Measures
Market Cap
2.06B
Enterprise Value
1.23B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
38.04
Price/Book (mrq)
2.72
Enterprise Value/Revenue
26.97
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.19%
Return on Equity (ttm)
-46.20%
Revenue (ttm)
45.56M
Net Income Avi to Common (ttm)
-241.6M
Diluted EPS (ttm)
-2.56
Balance Sheet and Cash Flow
Total Cash (mrq)
834.19M
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
-43.39M